系统综述与网络Meta分析:功能性消化不良药物的疗效
该系统综述与网络Meta分析检索至2020年7月的随机对照试验,评估成人功能性消化不良药物的疗效。共纳入71项RCT(19243例受试者),三环类抗抑郁药在低偏倚风险试验中疗效排名第一,但不良事件多于安慰剂;舒必利或左舒必利排名第一但试验质量低且仅86例接受活性治疗。
要点
- 三环类抗抑郁药在低偏倚风险试验中疗效排名第一,但不良事件较安慰剂更常见。
- 舒必利或左舒必利排名第一但试验质量低,仅86例接受活性治疗。
- 三环类抗抑郁药、组胺-2受体拮抗剂、标准剂量和低剂量质子泵抑制剂、舒必利或左舒必利、伊托必利和阿考替胺均比安慰剂更有效。
核心结论
- 三环类抗抑郁药、组胺-2受体拮抗剂、标准剂量和低剂量质子泵抑制剂、舒必利或左舒必利、伊托必利和阿考替胺均比安慰剂更有效。
研究设计与样本
- 系统综述与网络Meta分析,检索至2020年7月的医学文献,纳入评估成人功能性消化不良药物疗效的随机对照试验,共71项RCT(19243例受试者)。
主要发现
- 三环类抗抑郁药疗效排名第二(残留症状的RR=0.71;95%CI 0.58-0.87,SUCRA 0.87),在仅纳入低偏倚风险试验时排名第一。
- 舒必利或左舒必利疗效排名第一(RR=0.49;95%CI 0.36-0.69,SUCRA 0.99),但试验质量低且仅86例接受活性治疗。
- 三环类抗抑郁药比安慰剂更易引起不良事件。
局限性
- 舒必利或左舒必利的试验质量低,且仅86例接受活性治疗。
- 大多数使用三环类抗抑郁药的RCT招募的是对网络中其他药物无效的患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Functional dyspepsia (FD) is a relapsing and remitting condition affecting between 5% and 10% of people. Efficacious therapies are available, but their relative efficacy is unknown. AIM: To perform a systematic review with network meta-analysis to resolve this uncertainty. METHODS: We searched the medical literature through July 2020 for randomised controlled trials (RCTs) assessing efficacy of drugs for adults with FD, compared with each other, or placebo. Trials reported a dichotomous assessment of symptom status after completion of therapy. We pooled data using a random effects model. Efficacy was reported as a pooled relative risk (RR) of remaining symptomatic with a 95% confidence interval (CI) to summarise efficacy of each comparison tested. Relative ranking was assessed with surface under the cumulative ranking curve (SUCRA) probabilities. RESULTS: We identified 71 eligible RCTs (19 243 participants). Tricyclic antidepressants (TCAs) were ranked second for efficacy (RR of remaining symptomatic = 0.71; 95% CI 0.58-0.87, SUCRA 0.87), and first when only low risk of bias trials were included. Most RCTs that used TCAs recruited patients who were refractory to other drugs included in the network. Although sulpiride or levosulpiride were ranked first for efficacy (RR = 0.49; 95% CI 0.36-0.69, SUCRA 0.99), trial quality was low and only 86 patients received active therapy. TCAs were more likely to cause adverse events than placebo. CONCLUSIONS: TCAs, histamine-2 receptor antagonists, standard- and low-dose proton pump inhibitors, sulpiride or levosulpiride, itopride and acotiamide were all more efficacious than placebo for FD.
引用
- Ford AC, Moayyedi P, Black CJ, et al. Systematic review and network meta-analysis: efficacy of drugs for functional dyspepsia. Aliment Pharmacol Ther. 2020. PMID: 32936964. doi:10.1111/apt.16072
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。